<DOC>
	<DOCNO>NCT02097277</DOCNO>
	<brief_summary>The purpose study assess potential BMS-986036 treatment obese adult type-2 diabetes .</brief_summary>
	<brief_title>A Study Evaluate BMS-986036 Obese Adults With Type-2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Diagnosed type2 diabetes mellitus HbA1c â‰¥6.5 % le 10.0 % Body mass index 30.0 50.0 Any significant acute chronic medical illness Inability selfadminister subcutaneous injection Inability venipunctured Evidence organ dysfunction beyond consistent target population History allergy PEGylated compound Fibroblast growth factor 21 ( FGF21 ) relate compound</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>